Opdivo Qvantig Disease Interactions
There are 5 disease interactions with Opdivo Qvantig (hyaluronidase / nivolumab).
Nivolumab (applies to Opdivo Qvantig) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
There are no data available on the use of nivolumab-containing products in patients with severe hepatic impairment or autoimmune liver disease. No dose adjustment is recommended for patients with mild or moderate hepatic impairment during use of IV nivolumab; data not available for subcutaneous nivolumab. Monitor liver enzymes at baseline and periodically during therapy. Therapy with nivolumab-containing products may cause immune-mediated hepatitis and/or hepatotoxicity.
Nivolumab (applies to Opdivo Qvantig) pneumonitis
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pleuropulmonary Infection, History - Radiation Therapy
Use of nivolumab-containing products can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation.
PD-1/PD-L1 inhibitors (applies to Opdivo Qvantig) HSCT
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Transplantation
Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. It is recommended to follow patients closely for evidence of transplant-related complications and intervene promptly. The benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody before or after an allogeneic HSCT should be considered.
PD-1/PD-L1 inhibitors (applies to Opdivo Qvantig) myasthenia gravis
Moderate Potential Hazard, Moderate plausibility.
Myasthenic syndrome/myasthenia gravis (including exacerbation) has been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. Care should be exercised when using PD-1/PD-L1 blocking antibodies in patients with myasthenia gravis.
PD-1/PD-L1 inhibitors (applies to Opdivo Qvantig) organ transplant
Moderate Potential Hazard, Moderate plausibility.
Solid organ transplant rejection and other transplant (including corneal graft) rejection have been reported with the use of programmed death receptor-1/ligand-1 (PD-1/PD-L1) blocking antibodies. Care should be exercised when using PD-1/PD-L1 blocking antibodies in patients who have received a solid organ or other transplant.
Switch to professional interaction data
Opdivo Qvantig drug interactions
There are 662 drug interactions with Opdivo Qvantig (hyaluronidase / nivolumab).
More about Opdivo Qvantig (hyaluronidase / nivolumab)
- Opdivo Qvantig consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Fluorouracil
Fluorouracil systemic is used for anal cancer, breast cancer, breast cancer, palliative, cancer ...
Cisplatin
Cisplatin systemic is used for anal cancer, bladder cancer, blood cell transplantation, bone marrow ...
Capecitabine
Capecitabine systemic is used for anal cancer, breast cancer, breast cancer, metastatic, colorectal ...
Pembrolizumab
Pembrolizumab (Keytruda) is a monoclonal antibody cancer medicine used to treat
Methotrexate
Methotrexate is used to treat certain types of cancer of the breast, skin, head and neck, or lung ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.